Results 71 to 80 of about 365,877 (337)

Circ_0001944 Contributes to Glycolysis and Tumor Growth by Upregulating NFAT5 Through Acting as a Decoy for miR-142-5p in Non-Small Cell Lung Cancer

open access: yesCancer Management and Research, 2021
Yawei Dou,1 Wei Tian,1 Hongtao Wang,1 Shanshan Lv2 1Department of Thoracic Surgery, Shaanxi Province People’s Hospital, Xi’an, 710068, People’s Republic of China; 2Department of Cardiovascular Surgery, Xijing Hospital of Airforce ...
Dou Y, Tian W, Wang H, Lv S
doaj  

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC in Traditionally Unresectable Patients [PDF]

open access: green, 2021
Ke-Cheng Chen   +3 more
openalex   +1 more source

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. [PDF]

open access: yes, 2018
BACKGROUND:We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGFR) T790 M between liquid biopsy ...
Mambetsariev, Isa   +3 more
core   +1 more source

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

open access: yesFEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart   +7 more
wiley   +1 more source

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. [PDF]

open access: yes, 2020
Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response.
Boichard, Amélie   +2 more
core  

Applicability of mitotic figure counting by deep learning: a development and pan‐cancer validation study

open access: yesFEBS Open Bio, EarlyView.
In this study, we developed a deep learning method for mitotic figure counting in H&E‐stained whole‐slide images and evaluated its prognostic impact in 13 external validation cohorts from seven different cancer types. Patients with more mitotic figures per mm2 had significantly worse patient outcome in all the studied cancer types except colorectal ...
Joakim Kalsnes   +32 more
wiley   +1 more source

LncRNA GATA6-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer via Repressing microRNA-543 to Up-Regulating RKIP

open access: yesCancer Management and Research, 2020
Zixuan Gong,1,* Xiaoyu Chen,2,* YueChao Zhang,3,* Cheng Liu,4 Zhibing Wang,5 Xiaoyan Xu,6 Jun Zhu,7 Tongqing Xue4 1Department of Urology, Jiangsu Provincial People’s Hospital, Nanjing, Jiangsu Province, 211166, People’s Republic of China ...
Gong Z   +7 more
doaj  

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma [PDF]

open access: yes, 2018
Background The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient ...
Carnero Moya, Amancio   +5 more
core   +1 more source

Preservation of Extracellular Vesicle Integrity and Cargo Using Spiral Microfluidic Chip‐Based Separation

open access: yesAdvanced Materials Technologies, EarlyView.
A spiral microfluidic chip is compared with ultrafiltration for the separation of extracellular vesicles (EVs). The method preserves miRNA cargo and membrane integrity more effectively, resulting in intact vesicle morphology and consistent surface biomarker expression.
Huiseop Lee   +5 more
wiley   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

open access: yesHepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy